← Eichor
Condition: Purpura Thrombocytopenic Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Purpura Thrombocytopenic

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)
Phase 1 · 5 location(s) · Chongqing Peg-Bio Biopharm Co., Ltd. · NCT06880081Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
Phase 4 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT04518475Romiplostim for Oral TPO-RA Resistant ITP
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07612319V-IMMUNE® for Immune Thrombocytopenia
Phase 3 · 2 location(s) · On Pharma Importadora, Exportadora e Distribuidora de Medica · NCT06962631A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05214391A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopen
Phase 2/Phase 3 · 20 location(s) · argenx · NCT07194850A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Phase 1/Phase 2 · 45 location(s) · Eli Lilly and Company · NCT06721013Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura
NA · 1 location(s) · Sohag University · NCT07093606French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
Phase N/A · 1 location(s) · University Hospital, Toulouse · NCT02877706Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Phase 1/Phase 2 · 10 location(s) · CRISPR Therapeutics AG · NCT07549698Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Phase 1 · 77 location(s) · Chugai Pharmaceutical · NCT06371417Retrospective Epidemiological Study of Patients in the National Cohort of the French TMA Center
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07205861Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thromb
Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05338190Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura
Phase N/A · 1 location(s) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT07513948Association of TNFAIP3 With Immune-mediated TTP
NA · 1 location(s) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT06928233Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed
Phase 3 · 36 location(s) · Sanofi · NCT07007962Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia
Phase 1 · 1 location(s) · Gliknik Inc. · NCT07605845An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06799611BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases
Phase 1 · 1 location(s) · iCell Gene Therapeutics · NCT06787989Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)
Phase 1/Phase 2 · 1 location(s) · 920th Hospital of Joint Logistics Support Force of People's · NCT06352281High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patien
Phase 3 · 1 location(s) · Shandong University · NCT07559331A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05995054Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
Phase 2/Phase 3 · 1 location(s) · Chinese SLE Treatment And Research Group · NCT07657793A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytop
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06094881A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
Phase 1/Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06776510Study on Glucocorticoid Combined With Gamma Globulin and Ropristine N01 in Treatment of Initial Severe ITP
Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06686927TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Terminat
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06478537A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
Phase 1/Phase 2 · 20 location(s) · Climb Bio, Inc. · NCT07043946Longitudinal Cohort of Thrombosis and Hemostasis Diseases
Phase N/A · 5 location(s) · Peking University People's Hospital · NCT06727669Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (w
Phase 2 · 25 location(s) · Novartis Pharmaceuticals · NCT07039422
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.